# Filing Detail

Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001213900-25-015001
Filing Date
2025-02-19
Accepted
2025-02-19 06:06:16
Documents
6

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PROSPECTUS | ea0200357-15.htm | 424B4 | 4240673
2 | GRAPHIC | tanbio_logo.jpg | GRAPHIC | 36147
3 | GRAPHIC | tflowchart_001.jpg | GRAPHIC | 344373
4 | GRAPHIC | timage_005.jpg | GRAPHIC | 411207
5 | GRAPHIC | timage_006.jpg | GRAPHIC | 626201
6 | GRAPHIC | tycm_logo.jpg | GRAPHIC | 37162
| Complete submission text file | 0001213900-25-015001.txt |  | 6246562

Mailing Address FRIEDRICH-EBERT-ANLAGE 49 FRANKFURT AM MAIN 2M 60308
Business Address FRIEDRICH-EBERT-ANLAGE 49 FRANKFURT AM MAIN 2M 60308 4916096247281
Anbio Biotechnology (Filer) CIK: 0001982708 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-284106 | Film No.: 25637084
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)